GH1 and metabolic dysfunction-associated steatohepatitis: Given the evidence supporting a role for reduced GH/IGF-1 in pathogenesis, further study is needed to investigate whether strategies to augment GH/IGF-1 are safe and effective for some individuals with NASH.